Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein

Autores
Garanzini, Debora Patricia; Micucci, Matías; Torres Lopez, Annalies; Perez, Oscar; Calamante, Gabriela; Del Medico Zajac, Maria Paula
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
Instituto de Biotecnología
Fil: Garanzini, Debora Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Garanzini, Debora Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Micucci, Matías. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina
Fil: Torres Lopez, Annalies. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Torres Lopez, Annalies. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Perez, Oscar. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina
Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fuente
Viruses 17 (4) : 476 (April 2025)
Materia
Adenoviridae
Vectors
Glycoproteins
Rabies
Vaccines
Vectores
Glicoproteínas
Rabia
Vacuna
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/22085
Acceder
id INTADig_76aa75a6c82ce656ea2c7e7622f07367
oai_identifier_str oai:localhost:20.500.12123/22085
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoproteinGaranzini, Debora PatriciaMicucci, MatíasTorres Lopez, AnnaliesPerez, OscarCalamante, GabrielaDel Medico Zajac, Maria PaulaAdenoviridaeVectorsGlycoproteinsRabiesVaccinesVectoresGlicoproteínasRabiaVacunaRabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.Instituto de BiotecnologíaFil: Garanzini, Debora Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Garanzini, Debora Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Micucci, Matías. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); ArgentinaFil: Torres Lopez, Annalies. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Torres Lopez, Annalies. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Perez, Oscar. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); ArgentinaFil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMDPI2025-04-28T15:04:05Z2025-04-28T15:04:05Z2025-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/22085https://www.mdpi.com/1999-4915/17/4/4761999-4915https://doi.org/10.3390/v17040476Viruses 17 (4) : 476 (April 2025)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repograntAgreement/INTA/2023-PD-L06-I116, Implementación de tecnologías y nuevas estrategias preventivas y terapéuticas para el desarrollo sustentable y eficiente de la producción animal en el marco de Una Saludinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-04T09:51:02Zoai:localhost:20.500.12123/22085instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-04 09:51:02.755INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
title Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
spellingShingle Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
Garanzini, Debora Patricia
Adenoviridae
Vectors
Glycoproteins
Rabies
Vaccines
Vectores
Glicoproteínas
Rabia
Vacuna
title_short Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
title_full Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
title_fullStr Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
title_full_unstemmed Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
title_sort Protection against rabies induced by the non-replicative viral vectors MVA and Ad5 expressing rabies glycoprotein
dc.creator.none.fl_str_mv Garanzini, Debora Patricia
Micucci, Matías
Torres Lopez, Annalies
Perez, Oscar
Calamante, Gabriela
Del Medico Zajac, Maria Paula
author Garanzini, Debora Patricia
author_facet Garanzini, Debora Patricia
Micucci, Matías
Torres Lopez, Annalies
Perez, Oscar
Calamante, Gabriela
Del Medico Zajac, Maria Paula
author_role author
author2 Micucci, Matías
Torres Lopez, Annalies
Perez, Oscar
Calamante, Gabriela
Del Medico Zajac, Maria Paula
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Adenoviridae
Vectors
Glycoproteins
Rabies
Vaccines
Vectores
Glicoproteínas
Rabia
Vacuna
topic Adenoviridae
Vectors
Glycoproteins
Rabies
Vaccines
Vectores
Glicoproteínas
Rabia
Vacuna
dc.description.none.fl_txt_mv Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
Instituto de Biotecnología
Fil: Garanzini, Debora Patricia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Garanzini, Debora Patricia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Micucci, Matías. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina
Fil: Torres Lopez, Annalies. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Torres Lopez, Annalies. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Perez, Oscar. Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) “Dr. Carlos Malbrán”. Instituto Nacional de Producción de Biológicos. Servicio de Vacuna Antirrábica (SVAR); Argentina
Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Rabies is a zoonotic viral disease that is preventable through vaccination. Effective control strategies should follow the “One Health” concept, as targeting zoonotic pathogens at their animal source is the most effective and cost-efficient approach to protecting human health. The aim of this study was to develop and evaluate two third-generation anti-rabies vaccines based on non-replicative viral vectors, MVA and Ad5, both expressing rabies virus (RABV) glycoprotein (MVA-RG and Ad-RG). MVA-RG was produced using a platform developed in our laboratory, while Ad-RG was generated using a commercial kit. Protection against rabies was assessed in a mouse intracerebral (IC) RABV challenge model. Our results demonstrated that both vectors provided protection against RABV. MVA-RG and Ad-RG administered in two homologous doses conferred 60% and 60–100% protection against RABV challenge, respectively. The survival rate was influenced by the viral vector, the dose, and the immunization scheme. Remarkably, to our knowledge, our study is the first to report 100% protection against IC RABV challenge using a non-replicative Ad5 in a homologous immunization scheme. These promising results support future evaluation of this vaccine candidate in target animals.
publishDate 2025
dc.date.none.fl_str_mv 2025-04-28T15:04:05Z
2025-04-28T15:04:05Z
2025-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/22085
https://www.mdpi.com/1999-4915/17/4/476
1999-4915
https://doi.org/10.3390/v17040476
url http://hdl.handle.net/20.500.12123/22085
https://www.mdpi.com/1999-4915/17/4/476
https://doi.org/10.3390/v17040476
identifier_str_mv 1999-4915
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repograntAgreement/INTA/2023-PD-L06-I116, Implementación de tecnologías y nuevas estrategias preventivas y terapéuticas para el desarrollo sustentable y eficiente de la producción animal en el marco de Una Salud
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Viruses 17 (4) : 476 (April 2025)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1842341439411847168
score 12.623145

Publicaciones similares